Thromboembolism Clinical Trial
Official title:
Genetics Informatics Trial (GIFT) of Warfarin to Prevent Deep Venous Thrombosis (DVT)
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention. With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing strategies to improve the safety and effectiveness of clot prevention by customizing a popular blood thinner (warfarin) to each person's genetic and clinical profile. They hypothesize that the use of genetics to guide warfarin therapy will reduce the risk of venous thromboembolism (VTE) postoperatively. They further hypothesize that using a target international normalized ratio (INR) of 1.8 is non-inferior to using a target INR of 2.5 in VTE prevention.
The overall objective of the Genetics-InFormatics Trial (GIFT) of Warfarin to Prevent DVT is
to elucidate novel strategies to improve the safety and effectiveness of warfarin therapy.
With this study we directly respond to Health and Human Services (HHS) priorities to advance
the field of personalized medicine and to prevent venous thromboembolic (VTE) disease. In
2007, the Honorable Mike Leavitt, Secretary of HHS, announced the Personalized Health Care
Initiative and wrote that a key goal was, "… to use our personal genetic information to
tailor treatments more effectively to each patient."(1) Recently, President Obama and
Francis Collins (Director of the NIH) have made precision medicine a national priority.(2)
Previously, the Acting Surgeon General issued a Call to Action to reduce the number of cases
of VTE in the United States.(3) To facilitate precision dosing strategies for VTE
prevention, we have made publically available a non-profit, web application,
www.WarfarinDosing.org. A public version of www.WarfarinDosing.org estimates warfarin doses
for the initial 5 days of warfarin therapy. The version being evaluated in GIFT provides
doses for the initial 11 days of warfarin therapy.
Aim 1: To determine how pharmacogenetic-based warfarin therapy affects the safety and
effectiveness of warfarin therapy. The intensity of anticoagulant therapy is measured by the
International Normalized Ratio (INR). During initiation, the INR often falls outside the
therapeutic range. INRs that are too low predispose patients to VTE while supratherapeutic
INR values increase risk of bleeding.(4, 5) Previously, the FDA approved the label change of
warfarin/Coumadin™ to recommend considering lower initial doses in patients known to have
certain polymorphisms in genes affecting warfarin metabolism and sensitivity.(6) However,
whether this strategy improves the safety and effectiveness of warfarin therapy in general
is unknown. In particular, how this strategy affects subgroups with and without the genetic
variants of interest is also unknown.
Hypothesis 1: Pharmacogenetic therapy decreases the composite risk of a non-fatal VTE,
non-fatal major hemorrhage, death, or INR ≥ 4.0 in all patients, and/or in the subgroup of
patients whose pharmacogenetic and clinical predicted therapeutic maintenance doses differ
by > 1.0 mg/day. Based on our meta-analysis of prior trials(7), we anticipate 80% power to
simultaneously detect a 32% relative risk reduction in the composite outcome for
Aim 1 (as measured by a chi-square test). In the clinical arm, based on preliminary data, we
anticipate that the rate of the composite outcome will be 15.7% in the clinical arm and
10.7% in the pharmacogenetic arm. We obtained these estimates because they average a rate of
13.2%, which is the rate of the composite outcome for Aim 1 observed from the initial 775
GIFT participants. The power was calculated using a two-sided alpha of 0.05 for a test of
proportions, a drop-out rate of 2%, and a partitioned (two-sided) alpha with 0.044 allocated
to the whole population and 0.01 to the high-risk subgroup. Because of correlation between
these two subgroups, using these alphas preserves an overall type 1 error rate of 0.05.
Aim 2: To determine whether warfarin therapy with a target INR of 1.8 is non-inferior to
therapy with a target INR of 2.5 at preventing VTE or death in orthopedic patients. One
randomized trial (PREVENT) found that a target INR value of 1.5-2.0 prevented 64% of VTE
recurrence.(8) Although that trial excluded orthopedic patients, such an approach has been
endorsed by the American Academy of Orthopedic Surgeons (AAOS). On page 15 of the 2007 AAOS
guidelines (9) they offer the following recommendation for VTE prophylaxis around the time
of joint replacement: "Warfarin, with an INR goal of ≤ 2.0, starting either the night before
or the night after surgery, for 2-6 weeks." However, the AAOS grade the overall evidence for
VTE prophylaxis in this population as low (level III). The AAOS guidelines conflict with the
prior American College of Chest Physician (ACCP) guidelines,(10) which recommend, as one of
their (Grade 1A) options (page 338 S), using an "…adjusted-dose vitamin K antagonist (INR
target, 2.5; range 2.0 to 3.0)." Because lower target INR values may reduce the risk of
hemorrhage and simplify warfarin management(8) we propose to test the following:
Hypothesis 2: For prevention of non-fatal VTE or death, a target INR of 1.8 will be
non-inferior to a higher target INR (2.5). Using a non-inferiority margin of 3% absolute
risk reduction in non-fatal VTE or death and an estimated composite rate of 5.56% (based on
preliminary GIFT data), we will have 83% power to detect the non-inferiority of a target INR
of 1.8 in 1600 patients.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
Terminated |
NCT02475187 -
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
|
||
Recruiting |
NCT00982514 -
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
|
N/A | |
Completed |
NCT01420809 -
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
|
N/A | |
Terminated |
NCT00206089 -
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
|
Phase 3 | |
Completed |
NCT00014352 -
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
Completed |
NCT02935751 -
Apixaban Discontinuation Prior to Major Surgery
|
||
Terminated |
NCT02579122 -
REVIparin-BRIDging-in a General Practice Setting in GErmany
|
||
Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
Terminated |
NCT00662688 -
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT00260988 -
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
|
Phase 2/Phase 3 | |
Terminated |
NCT00031837 -
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT03877770 -
DVT After Cardiac Procedure
|
||
Completed |
NCT00024297 -
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
|
N/A | |
Recruiting |
NCT06118957 -
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
|
Phase 2 |